MediciNova Analyst Lowers Price Target to $5.00, Maintains Buy Rating

miércoles, 18 de junio de 2025, 2:11 am ET1 min de lectura
MNOV--

MediciNova (MNOV) stock received a "Buy" rating from B. Riley Securities analyst Mayank Mamtani, with a lowered price target of $5.00 USD, down from $6.00. The analyst maintains confidence in MediciNova's prospects, despite the 16.67% decrease in price target. Wall Street analysts forecast an average target price of $7.50, implying a 476.92% upside from the current price of $1.30.

MediciNova Analyst Lowers Price Target to $5.00, Maintains Buy Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios